Nirogy Therapeutics: Funding, Investors & Team (Sep 2026)
Nirogy Therapeutics is a biotechnology company developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncology as well as autoimmune diseases.
Nirogy Therapeutics has raised $16.5M across 1 funding round on record, the most recent a Series A of $16.5M announced in Jan 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Nirogy Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2021.
Nirogy Therapeutics Funding Rounds
Nirogy Therapeutics Founders and Leadership Team
Contact details for the Nirogy Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Nirogy Therapeutics Funding Compared to Other Biotechnology Startups
Nirogy Therapeutics' latest round of $16.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Nirogy Therapeutics in Biotechnology and Natick
Companies Similar to Nirogy Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Nirogy Therapeutics Funding FAQs
What does Nirogy Therapeutics do?
Nirogy Therapeutics is a biotechnology company developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncology as well as autoimmune diseases.
How much funding has Nirogy Therapeutics raised?
Nirogy Therapeutics has raised $16.5M across 1 round on record. The most recent is a Series A of $16.5M announced in Jan 2021.
When did Nirogy Therapeutics last raise funding?
Nirogy Therapeutics' most recent funding round on record is a Series A of $16.5M, announced in Jan 2021.
Who is the CEO of Nirogy Therapeutics?
Vincent Sandanayaka is listed as CEO at Nirogy Therapeutics.
Where is Nirogy Therapeutics headquartered?
Nirogy Therapeutics is based in Natick, Massachusetts, United States.
How many employees does Nirogy Therapeutics have?
Nirogy Therapeutics is in the 1-10 employee band.
How does Nirogy Therapeutics' funding compare to other Biotechnology startups?
Nirogy Therapeutics' latest round of $16.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Nirogy Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nirogy Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.